DIFFERENCES IN THE TRANSCRIPTIONAL RESPONSE TO FULVESTRANT AND OESTROGEN DEPRIVATION IN ER-POSITIVE BREAST CANCER

PURPOSE: Endocrine therapies include aromatase inhibitors and the selective oestrogen receptor (ER) down-regulator fulvestrant. This study aimed to determine if the reported efficacy of fulvestrant over anastrozole, and high- over low-dose fulvestrant, reflect distinct transcriptional responses. EXP...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Patani, Neill, Dunbier, Anita, Anderson, Helen, Ghazoui, Zara, Ribas, Ricardo, Anderson, Elizabeth, Gao, Qiong, A’hern, Roger, Mackay, Alan, Lindemann, Justin, Wellings, Robert, Walker, Jill, Kuter, Irene, Martin, Lesley-Ann, Dowsett, Mitch
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4119788/
https://ncbi.nlm.nih.gov/pubmed/24916694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1378
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires